Decreased Expression of Tumor Necrosis Factor-α and Regression of Hypertrophy After Nonsurgical Septal Reduction Therapy for Patients With Hypertrophic Obstructive Cardiomyopathy
Key result
Nonsurgical septal reduction therapy significantly decreased myocyte size, collagen content, and TNF-alpha levels, and reduced left ventricular hypertrophy and chamber stiffness in HOCM patients.
Why the study?
Does nonsurgical septal reduction therapy reduce markers of hypertrophy and TNF-alpha expression in patients with hypertrophic obstructive cardiomyopathy?
Population
15 patients with hypertrophic obstructive cardiomyopathy (HOCM)
Comparison
Nonsurgical septal reduction therapy (NSRT) vs Baseline (pre-procedure) measurements
Design
Cohort
Authors
Discussion
Loading...
Member takes
Implication
Does not support practice change in HOCM; leaves open need for randomized outcome trials.
Study Design
Type
Observational (n=15)
Structured PICO
Does nonsurgical septal reduction therapy reduce markers of hypertrophy and TNF-alpha expression in patients with hypertrophic obstructive cardiomyopathy?
P
Population
15 patients with hypertrophic obstructive cardiomyopathy evaluated at baseline and after successful nonsurgical septal reduction therapy.
I
Intervention
Nonsurgical septal reduction therapy (NSRT)
C
Comparator
Baseline (pre-procedure) measurements
O
Outcome
Changes in myocardial TNF-alpha levels, myocyte size, collagen content, left ventricular hypertrophy (LVH), end-diastolic volume, and chamber stiffnesssurrogate
Nonsurgical septal reduction therapy in HOCM patients significantly reduces myocardial TNF-alpha expression, myocyte size, and collagen content, suggesting a reversal of pathological hypertrophy.
Cite This Study
Nagueh et al. (2001) conducted an observational in Hypertrophic obstructive cardiomyopathy (HOCM) (n=15). Nonsurgical septal reduction therapy (NSRT) vs. Baseline was evaluated on Myocardial function and markers of hypertrophy including TNF-alpha, myocyte size, and collagen content. Nonsurgical septal reduction therapy significantly decreased myocyte size, collagen content, and TNF-alpha levels, and reduced left ventricular hypertrophy and chamber stiffness in HOCM patients.